The main differences observed between patients who received early CS or not were a higher rate of developing at least one hyperglycemia event: 46 (69.7%) vs. 59 (24.9%), (p < 0.01), and a higher median daily dose of insulin: 27.2 Ui [4.4; 58.4] vs. 6.2 Ui [0; 37.1], (p< 0.01), respectively. This evidence concerns the gene INS and Hyperglycemia.